Close Menu
Beverly Hills Examiner

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Here are the top AI agents that can live in your text messages  | TechCrunch

    November 21, 2026

    You either take the wheel, or were going to run into the wall: The founder who sold Wrike for $2.25 billion forced his engineers to build around AI | Fortune

    November 21, 2026

    Startup sues Apple in India over tap-to-share contacts feature | TechCrunch

    November 21, 2026
    Facebook X (Twitter) Instagram
    Beverly Hills Examiner
    • Home
    • US News
    • Politics
    • Business
    • Science
    • Technology
    • Lifestyle
    • Music
    • Television
    • Film
    • Books
    • Contact
      • About
      • Amazon Disclaimer
      • DMCA / Copyrights Disclaimer
      • Terms and Conditions
      • Privacy Policy
    Beverly Hills Examiner
    Home»Science»Pancreatic Cancer Vaccine Shows Promise in Small Initial Trial
    Science

    Pancreatic Cancer Vaccine Shows Promise in Small Initial Trial

    By AdminMay 12, 2023
    Facebook Twitter Pinterest LinkedIn WhatsApp Email Reddit Telegram
    Pancreatic Cancer Vaccine Shows Promise in Small Initial Trial

    [ad_1]

    Pancreatic Cancer Vaccine Shows Promise in Small Initial Trial

    Pancreatic cancer is one of the deadliest forms of cancer, with very few effective treatments. But messenger RNA (mRNA) vaccines—famous for their ability to prevent COVID—are starting to show some promise against the lethal cancer. In a recent early-stage trial, half of pancreatic cancer patients who received a personalized mRNA cancer vaccine after surgery did not have a recurrence of the tumor a year and a half later. The trial, which was described in a study published on Wednesday in Nature, was small—with just 16 patients—and it will need to be replicated in larger studies.

    “I am very supportive of the findings,” says Drew Weissman, director of vaccine research and director of the Institute for RNA Innovation at the University of Pennsylvania, who is a pioneer of mRNA vaccines but was not involved in the new paper. He adds that “it is not a definitive proof-for-use study. Larger studies are needed to determine effectiveness.”

    Pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer, has a mortality rate of 88 percent. It is the third leading cause of death from cancer in the U.S. and is becoming more common. Surgery is the main form of treatment, but the cancer has a 90 percent recurrence rate at seven to nine months. Chemotherapy is only partially effective at delaying recurrence. Other treatments, such as immunotherapy, are mostly ineffective.

    Pancreatic cancer often goes undetected until its later stages, when it is harder to treat. One reason it is so sneaky is that it generates relatively few of a type of surface proteins, called neoantigens, that mark it as foreign and trigger an immune response. Scientists had noticed that people who survived pancreatic cancer had a stronger response to these neoantigens from T cells, a type of immune cell.

    In the new study, Vinod Balachandran, an assistant attending surgeon at Memorial Sloan Kettering Cancer Center in New York City, and his colleagues targeted pancreatic cancer patients’ own tumor neoantigens using mRNA technology—the same technology used to create the remarkably successful COVID vaccines. The experimental vaccines used by Balachandran and his colleagues were produced by BioNTech, a company that developed one of the COVID vaccines with Pfizer. The researchers vaccinated a total of 16 patients. After surgically removing the tumors, they treated the patients with mRNA vaccines tailored to each person’s specific cancer, as well as an adjuvant, a substance that increases the effects of vaccines. Fifteen of the participants were also treated with chemotherapy.

    Eight of the 16 patients generated a strong T cell response to the vaccines. At a median follow-up time of 18 months after the treatment, these individuals had longer survival, without a recurrence of their cancer.

    The study was small and involved only white patients. And the therapy—which is expensive—does not work for everyone with pancreatic cancer. Nevertheless, experts say it is a promising development for a disease with such limited treatment options.

    [ad_2]

    Original Source Link

    Share. Facebook Twitter Pinterest LinkedIn WhatsApp Email Reddit Telegram
    Previous ArticleI 7 Star Recalls Watching Tom Cruise’s Daring Motorcycle Stunt
    Next Article The Boring Future of Generative AI

    RELATED POSTS

    Voyager 1 Beat the Odds and Is Still Working a Light-Day Away From Earth

    November 18, 2026

    The Dark Side of the Moon Was the Brightest Part of 2026

    November 17, 2026

    Just 400 US Data Centers Use More Electricity Than Michigan

    November 16, 2026

    The EPAs Chemical-Detecting Plane Isnt Doing Its Job Anymore

    November 16, 2026

    Its Getting Too Dry for Even Cactuses to Survive

    November 15, 2026

    New Species of Giant Fungus Discovered in China Grows up to 20 Inches Tall

    November 15, 2026
    latest posts

    Here are the top AI agents that can live in your text messages  | TechCrunch

    Rather than downloading another app, a growing number of agents can simply be texted like…

    You either take the wheel, or were going to run into the wall: The founder who sold Wrike for $2.25 billion forced his engineers to build around AI | Fortune

    November 21, 2026

    Startup sues Apple in India over tap-to-share contacts feature | TechCrunch

    November 21, 2026

    The US to become first nation to fully shun a UN Human Rights Council review

    November 21, 2026

    Bassam Tariq Says Marvels Scrapped Blade Reboot Taught Him Lifes Too Short to Make Sh** Films

    November 21, 2026

    Grimes Releases Two New Psy Opera Songs

    November 20, 2026

    Book Riots Deals of the Day for November 20, 2026

    November 20, 2026
    Categories
    • Books (1,621)
    • Business (6,526)
    • Cover Story (17)
    • Film (6,460)
    • Lifestyle (4,501)
    • Music (6,536)
    • Politics (6,512)
    • Science (5,866)
    • Technology (6,464)
    • Television (6,157)
    • Uncategorized (3)
    • US News (6,509)
    popular posts

    We can’t let short-term crises derail efforts to tame climate change

    [ad_1] Jeff J Mitchell/Getty Images SIX months ago world leaders made grand promises to act…

    Miles Teller to Host Premiere, Plus Megan Thee Stallion & More

    September 20, 2022

    16 Best Travel Coffee Mugs (2022): Insulated, Steel, Thermal

    July 11, 2022

    Goodbye Gloomy Face! These Are Ultimate Guide To Look Pretty For Passport Photos – Ferbena.com

    August 26, 2023
    Archives
    Browse By Category
    • Books (1,621)
    • Business (6,526)
    • Cover Story (17)
    • Film (6,460)
    • Lifestyle (4,501)
    • Music (6,536)
    • Politics (6,512)
    • Science (5,866)
    • Technology (6,464)
    • Television (6,157)
    • Uncategorized (3)
    • US News (6,509)
    About Us

    We are a creativity led international team with a digital soul. Our work is a custom built by the storytellers and strategists with a flair for exploiting the latest advancements in media and technology.

    Most of all, we stand behind our ideas and believe in creativity as the most powerful force in business.

    What makes us Different

    We care. We collaborate. We do great work. And we do it with a smile, because we’re pretty damn excited to do what we do. If you would like details on what else we can do visit out Contact page.

    Our Picks

    Grimes Releases Two New Psy Opera Songs

    November 20, 2026

    Book Riots Deals of the Day for November 20, 2026

    November 20, 2026

    Chips can survive the space environment. Can their financing? | TechCrunch

    November 20, 2026
    © 2026 Beverly Hills Examiner. All rights reserved. All articles, images, product names, logos, and brands are property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Terms & Conditions and Privacy Policy.

    Type above and press Enter to search. Press Esc to cancel.

    We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
    Cookie SettingsAccept All
    Manage consent

    Privacy Overview

    This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
    Necessary
    Always Enabled
    Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
    CookieDurationDescription
    cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
    cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
    cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
    cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
    cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
    viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
    Functional
    Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
    Performance
    Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
    Analytics
    Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
    Advertisement
    Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
    Others
    Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
    SAVE & ACCEPT